Abstract:
Pharmaceutical market is a typical market with information asymmetry, and which can lead to “lemons” problem. In all developed countries, firms must receive regulatory approval to market a pharmaceutical product. Such administrative department including SFDA, EMA, FDA and so on. Chinese materia medica is a special part of pharmaceutical market in China. The management of Chinese materia medica is a special challenge in China.
Key words:
Information asymmetry; Pharmacopoeia standards; Drug safety TCM administration; Third-party certification
Fund：
National Natural Science Foundation of China (81130070,81072989); National Science and Technology Support Program (2012BAI29B02,2012BAI28B002)
Reference:
Yang, G., Wang, N., Guo, L., Wang, Y., Huang, L., & Liu, J. (2013). Management of Chinese materia medica market based on information asymmetry. China Journal of Chinese Materia Medica, 38(23), pp.4168-4173. （《从信息不对称的角度分析《中国药典》标准管理中药的局限性》）
Link: